Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
[引用][C] Combination Therapy with anti-HIV-1 Antibodies Maintains Viral Suppression
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - Nature, 2018 - pure.mpg.de
Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - Nature, 2018 - europepmc.org
HIV-1-infected individuals require lifelong antiretroviral therapy (ART) because treatment
interruption leads to rapid rebound viremia. Here we report on a phase 1b clinical trial in …
interruption leads to rapid rebound viremia. Here we report on a phase 1b clinical trial in …
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - …, 2018 - ui.adsabs.harvard.edu
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
P Mendoza, H Gruell, L Nogueira, JA Pai… - …, 2018 - tobias-lib.ub.uni-tuebingen.de
Combination therapy with anti-HIV-1 antibodies maintains viral suppression Combination
therapy with anti-HIV-1 antibodies maintains viral suppression DSpace Repositorium (Manakin …
therapy with anti-HIV-1 antibodies maintains viral suppression DSpace Repositorium (Manakin …
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - Nature, 2018 - kups.ub.uni-koeln.de
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
[引用][C] Combination therapy with anti-HIV-1 antibodies maintains viral suppression
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - Nature, 2018 - cir.nii.ac.jp
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - Nature, 2018 - econpapers.repec.org
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - Nature, 2018 - nature.com
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
[HTML][HTML] Combination therapy with anti-HIV-1 antibodies maintains viral suppression
P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler… - Nature, 2018 - ncbi.nlm.nih.gov
HIV-1-infected individuals require lifelong antiretroviral therapy (ART) because treatment
interruption leads to rapid rebound viremia. Here we report on a phase 1b clinical trial in …
interruption leads to rapid rebound viremia. Here we report on a phase 1b clinical trial in …